MSK Announces Closing of Merger and Initial NASDAQ Listing of Variation Biotechnologies
Mitchell, Silberberg & Knupp* announced that its client Variation Biotechnologies (US) Inc. (“VBI”) completed a merger with Paulson Capital (Delaware), Inc. (NASDAQ: PLCC) concurrently with two private placements totaling $16.25 million from biotech venture capital investors and other institutional investors. The post-merger entity, named VBI Vaccines Inc., is listed on the NASDAQ Capital Market under the symbol “VBIV”.
The Mitchell, Silberberg & Knupp* team was led by Co-Managing Partner, Kevin Friedmann, and included Gabrielle Napolitano and Bryan Wasser. VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets.
*Handled through the predecessor law firm of Richardson Patel LLP.